HC Wainwright Reaffirms “Buy” Rating for Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 52.77% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. JMP Securities assumed coverage on shares of Assembly Biosciences in a research note on Wednesday, September 24th. They set a “market outperform” rating and a $38.00 target price for the company. Guggenheim boosted their price objective on shares of Assembly Biosciences from $31.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Citigroup assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set an “outperform” rating on the stock. Finally, Mizuho set a $40.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a research note on Thursday, November 20th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Assembly Biosciences Stock Performance

NASDAQ ASMB opened at $32.73 on Monday. The stock has a 50-day simple moving average of $33.52 and a 200 day simple moving average of $25.72. Assembly Biosciences has a twelve month low of $7.75 and a twelve month high of $39.71. The stock has a market capitalization of $517.79 million, a PE ratio of -6.83 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%.The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $7.46 million. As a group, equities research analysts forecast that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors have recently added to or reduced their stakes in ASMB. Farallon Capital Management LLC bought a new stake in shares of Assembly Biosciences in the 3rd quarter valued at approximately $31,426,000. RA Capital Management L.P. acquired a new stake in Assembly Biosciences in the 3rd quarter valued at $26,122,000. Commodore Capital LP bought a new stake in Assembly Biosciences in the third quarter valued at $25,600,000. Vanguard Group Inc. raised its stake in Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares in the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in Assembly Biosciences during the third quarter worth $6,425,000. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.